Registration 

Type Early Bird Rate Regular Rate 
Member Rate $400 $475
Non-Member Rate $500 $575
Trainee Rate $300 $375
Industry Rate (Companies Not Sponsoring the Event)  $900 $900

Register Today

The early bird registration rate ends at 11:59 p.m. CT on Monday, September 14th.  

Registration for the conference will close on Thursday, November 12th at 4 p.m. CT. For any registration questions, please email info@astct.org.

Agenda

Day 1: Friday, November 13
6:00 AM Registration Opens 
7:15 – 8:00 AM Breakfast Product Theater
Presented by Iovance

8:10 – 8:15 AM

 Welcome to the ASTCT 5th International Conference on Toxicities of Transplantation and Cellular Therapies
Christina Cho, MD; Hackensack University Medical Center

8:15 – 9:15 AM
 

 Keynote: Endothelial Cell Damage - A Target for Mitigating Toxicities
Stella Davies, MBBS, PhD, MRCP; Cincinnati Children’s
9:15 – 10:55 AM
 

 

Main Session 1: 75+: The New Frontier in alloHCT
Organizing Committee Session Chairs: Sergio Giralt, MD; Memorial Sloan Kettering Cancer Center and William Wood, MD; University of North Carolina

Microbiome in Older Adults Undergoing alloHCT 
Melody Smith, MD, MS; Stanford

Transplant and Cell Therapy for Octogenarians: What are we doing and what are the outcomes?
Doug Rizzo, MD; Medical College of Wisconsin

Strategies to reduce NRM in older patients: What is most promising and how low can we go?
Andrew Artz, MD; City of Hope

Debate: 75+ RIC alloHCT vs other
Mariam Nawas, MD; University of Chicago

Sergio Giralt, MD; Memorial Sloan Kettering Cancer Center
Panel Discussion; Q&A
10:55 – 11:10 AM Break
11:10 AM – 12:50 PM
 		 Main Session 2: Rare but Serious CAR T Toxicities - Beyond CRS & ICANS
Session Chair: Nirali Shah, MD, MSc; National Cancer Institute  
Organizing Committee Session Chair: Melody Smith, MD, MS; Stanford 

IEC-EC 
Lekha Mikkilineni, MD; Stanford

Tumor inflammation-associated neurotoxicity
Jasia Mahdi, MD; Texas Children’s

IEC-HS
Nirali Shah, MD, MSc; National Cancer Institute

Pediatric Specific (NRM/ICAHT/ICANs)
Regina Myers, MD, MSCE; Children’s Hospital of Philadelphia
Panel Discussion; Q&A
12:50 - 1:50 PM Lunch Break 
1:00 - 1:45 PM  Lunch Product Theater 
Presented by Incyte
1:50 - 3:30 PM
 		 Main Session 3: Matters of the Heart and Kidneys: Cardio-Renal Comorbidity and Toxicity Management
Session Chair: Rebecca Olin, MD, MS; UCSF
Organizing Committee Session Chair: Mariam Nawas, MD; University of Chicago 

CARE-BMT: Cardiovascular Risk Across the Hematopoietic Cell Transplantation Continuum
Alexi Vasbinder, PhD, RN; University of Washington

PTCy and Cardiac Toxicity
Rebecca Olin, MD, MS; UCSF

CAR T and Lymphodepletion Considerations in Renal Insufficiency
Surbhi Sidana, MD; Stanford

CAR T in Solid Organ Transplant Recipients
Samuel Yamshon, MD; NYU Langone Health
Panel Discussion; Q&A
3:30 -3:45 PM Break
3:45 - 5:25 PM
 		 Main Session 4: Expanding Frontiers in Cell Therapy: Autoimmune Disease and Solid Tumors — Emerging Toxicities and Challenges
Session Chair: Ran Reshef, MD, MSc; Columbia University 
Organizing Committee Session Chair: Michael Scordo, MD; Memorial Sloan Kettering Cancer Center

Emergent toxicities and challenges related to cellular therapies for autoimmune diseases
Ran Reshef, MD, MSc; Columbia University

Unique and Specific Toxicities related to TILs
Alexandra Haugh, MD, MPH; Massachusetts General Hospital

Toxicity Challenges in Solid Tumor CAR T Development
Saul Priceman, PhD; Keck School of Medicine at USC

Debate: AutoHCT vs. CAR T in autoimmune disease specifically MS
Jeff Dunn, MD; Stanford

Guillermo J. Ruiz-Argüelles, MD, FRCP, MACP; Clinica Ruiz
Panel Discussion; Q&A
5:30 - 6:30 PM Networking and Poster Reception
Day 2: Saturday, November 14

Housing 

The InterContinental Chicago Magnificent Mile

505 N Michigan Ave
Chicago, IL 60611
+1 (312) 944-4100

Registered attendees will receive the housing link to secure discounted room rates in their official registration confirmation email. 

Room Rate

$249 plus any applicable taxes and fees (single/double). 

Housing Rate Cutoff

To take advantage of the discounted room rate, be sure to book your reservation on or before October 22, 2026 or until rooms are sold out — whichever occurs first. After October 22, the room block will be released and the negotiated room rates may not be available. Please make sure the hotel is aware of any special needs. They will assign specific room types and any other requests based on availability. 

Deposits

Please have your credit card information on hand upon booking your reservation. The InterContinental Chicago Magnificent Mile requires each individual reservation be guaranteed with a deposit equal to one night's room and tax. 

Changes or Cancellations

The InterContinental Chicago Magnificent Mile requires that you cancel your reservation (72) hours prior to your arrival. The deposit of one night's room and tax will be forfeited for cancellations made less than (72) hours from arrival. Please call the hotel directly to make a cancellation and keep your cancellation confirmation number for your records. 

Confirmations

The hotel will send you a confirmation to the email used in booking your reservation using the customized online reservation link provided by ASTCT. Review it carefully for accuracy and keep a copy for your records. 

Abstracts

ASTCT is currently accepting abstracts for the Toxicities Conference, giving you the opportunity to present your research to a broad audience. We welcome abstract submissions from fellows, residents, nurses, APPs, pharmacists, and physicians. The top three best abstracts will receive complimentary registration to the conference. The abstract submission window will close on Tuesday, September 1.

Submit Your Abstract

Abstract Submission Criteria

Abstracts will be scored based on the following criteria: 

  • Importance and Relevance: Is a clear rationale for the work provided? Does the study address an important question? Do its findings have the potential to advance the field of blood and marrow or cellular therapies? 
  • Originality and Innovation: Is the work novel? Does it present new findings and/or address a problem using an original or improved approach? 
  • Quality of Methods and Writing: Are methods well described and valid to answer the question? Is the abstract clear and well written? Is the abstract within the 300-word limit? 

Please note that the abstract submission form does not have a tracker for word count. We recommend that you prepare your abstract submission in a Word document to confirm that you stay within the 300-word limit.

The top three abstracts will receive complimentary registration to the meeting. All accepted abstracts will be required to present their posters at the conference during the poster reception on Friday, November 13. 

Responsibility of Abstract Authors

The Presenting Author is responsible for the following:

  • Ensuring that all authors have read the abstract and agreed to be co-authors. 
  • Notifying all co-authors of any additions, deletions, and changes to the program, as may be communicated by the 5th International Conference on Toxicities of Transplantation and Cellular Therapies. 
  • Obtaining all the conflict-of-interest disclosure information from co-authors. 
  • Making certain that abstracts are complete (tables included and labeled) and written in clear, concise and grammatically correct English, so that reviewers are able to focus solely on the scientific merits of the submission. For authors with any questions regarding the clarity, grammar or spelling of their abstract, we encourage identifying and using an independent reviewer to edit the abstract prior to submission. 

Please contact Haedyn Smith with any questions regarding your submission.

Accreditation

This activity is jointly provided by The France Foundation and the American Society for Transplantation and Cellular Therapy (ASTCT).

TARGET AUDIENCE

This educational activity is intended for physicians, advanced practice providers, and nurses who treat or refer patients for HCT or immune effector cell therapies.

STATEMENT OF NEED

The conference brings together experts and thought leaders from around the world to discuss the mechanism of toxicities and symptom burden after hematopoietic cell transplantation (HCT) and cellular therapies; current advances in the field; and best practices to both prevent and treat these toxicities and symptoms.

The program will include a wide range of pre-clinical, translational and clinical topics, will offer networking opportunities and a dedicated poster reception showcasing research in toxicities.

EDUCATIONAL ACTIVITY LEARNING OBJECTIVES

Upon completion of this course, the participants should be able to:

  • Analyze mechanisms and drivers of toxicity in HCT and cellular therapies
    Evaluate the biological and clinical factors contributing to toxicities in hematopoietic cell transplantation (HCT) and cellular therapies, including aging, frailty, and comorbidities, to improve risk stratification and individualized patient care.
  • Apply emerging evidence to toxicity prevention and management
    Incorporate evolving clinical evidence and therapeutic advances—including recognition of rare CAR T–associated toxicities, cardio-renal complications, and the expanding use of cellular therapies in older adults, autoimmune diseases, and solid tumors—to enhance prevention, early detection, and management strategies.
  • Assess innovations shaping the future of toxicity monitoring and care
    Examine how emerging technologies and translational approaches, including artificial intelligence, biomarker-driven research, and novel monitoring strategies, may improve clinical decision-making, toxicity surveillance, and outcomes in HCT and cellular therapy.

ACCREDITATION STATEMENT

 

In support of improving patient care, this activity has been planned and implemented by The France Foundation and the American Society for Transplantation and Cellular Therapy. The France Foundation is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the health care team.

 

Physician Credit Designation

The France Foundation designates this live activity for a maximum of 10.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

METHOD OF PARTICIPATION/HOW TO RECEIVE CREDIT

  • Review the activity objectives and CME/CE information.
  • Participate in the CME/CE activity.
  • Complete the course evaluation.
  • If you are requesting educational credits or a certificate of participation, your certificate will be available for download.

DISCLOSURE POLICY

In accordance with the ACCME Standards for Commercial Support, The France Foundation (TFF) and the American Society for Transplantation and Cellular Therapy (ASTCT) require that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. TFF And ASTCT resolve all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all their educational programs.

Furthermore, TFF and ASTCT seek to verify that all scientific research referred to, reported, or used in a CME/CE activity conforms to the generally accepted standards of experimental design, data collection, and analysis. TFF and ASTCT are committed to providing learners with high-quality CME/CE activities that promote improvements in health care and not those of a commercial interest.

PLANNER, STAFF, AND FACULTY DISCLOSURES

Planner, staff, and faculty disclosures will be available at the conference.

DISCLOSURE OF UNLABELED USE:

TFF and ASTCT require CME faculty (speakers) to disclose when products or procedures being discussed are off label, unlabeled, experimental and/or investigational, and any limitations on the information that is presented, such as data that are preliminary, or that represent ongoing research, interim analyses, and/or unsupported opinion. Faculty in this activity may discuss information about pharmaceutical agents that are outside of US Food and Drug Administration approved labeling.

This information is intended solely for continuing medical education and is not intended to promote off-label use of these medications. TFF and ASTCT do not recommend the use of any agent outside of the labeled indications. If you have questions, contact the Medical Affairs Department of the manufacturer for the most recent prescribing information.

DISCLAIMER

TFF and ASTCT present this information for educational purposes only. The content is provided solely by faculty who have been selected because of recognized expertise in their field. Participants have the professional responsibility to ensure that products are prescribed and used appropriately on the basis of

their own clinical judgment and accepted standards of care. The France Foundation, ASTCT, and the commercial supporter(s) assume no liability for the information herein.

Information

If you have questions about this CME/CE activity, please contact The France Foundation at 860-434-1650 or htarbox@francefoundation.com.